Literature DB >> 948542

Renal abnormalities and vascular complications in primary hyperaldosteronism. Evidence on tertiary hyperaldosteronism.

D G Beevers, J J Brown, J B Ferriss, R Fraser, A F Lever, J I Robertson, M Tree.   

Abstract

The frequency of underlying renal or renal artery disease, and the incidence of vascular complications were reviewed in a series of 136 cases of primary hyperaldosteronism. This was in order to investigate the possible existence of 'tertiary' hyperaldosteronism, and to examine the commonly held view that primary hyperaldosteronism is a relatively benign form of hypertension. Ten cases (7-4 per cent) had evidence of renal artery stenosis and eleven (8-1 per cent) parenchymatous renal disease. In comparison with the reported frequency in large general series of hypertensives, these data show no evidence of an excess of underlying renal disease. It is unlikely, therefore, that autonomous aldosterone secreting adenomata occur commonly as a consequence of prolonged secondary hyperaldosteronism. Four cases (2-9 per cent) had evidence of the malignant-phase of hypertension, and over a mean observation time of 5-9 years, 31 cases (22-8 per cent) developed 39 vascular complications. It appears, therefore, that vascular complications are not rare in primary hyperaldosteronism, and early and effective treatment is thus necessary.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 948542

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  12 in total

1.  Lack of difference between malignant and accelerated hypertension.

Authors:  M E Ahmed; J M Walker; D G Beevers; M Beevers
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-25

2.  Malignant hypertension and asymmetric septal hypertrophy in a 43-year-old black man.

Authors:  J C Rutledge; A Eng; J Silva
Journal:  West J Med       Date:  1986-09

3.  The management of patients with primary aldosteronism.

Authors:  P O Granberg; U Adamson; K H Cohn; B Hamberger; P E Lins
Journal:  World J Surg       Date:  1982-11       Impact factor: 3.352

Review 4.  Rationale for the use of aldosterone antagonists in congestive heart failure.

Authors:  Ricardo Rocha; Gordon H Williams
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Conn's syndrome and bilateral renal artery stenosis in the presence of multiple renal arteries.

Authors:  B Glodny; S Cromme; K Wörtler; R Herwig; K Kisters; G Winde
Journal:  J Endocrinol Invest       Date:  2001-04       Impact factor: 4.256

6.  Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. The Research Committee of Disorders of Adrenal Hormones in Japan.

Authors:  R Takeda; T Matsubara; I Miyamori; H Hatakeyama; T Morise
Journal:  J Endocrinol Invest       Date:  1995-05       Impact factor: 4.256

7.  Intrarenal hemodynamics in primary aldosteronism before and after treatment.

Authors:  Leonardo A Sechi; Alessandro Di Fabio; Massimo Bazzocchi; Alessandro Uzzau; Cristiana Catena
Journal:  J Clin Endocrinol Metab       Date:  2009-01-13       Impact factor: 5.958

Review 8.  Malignant or accelerated hypertension.

Authors:  N D Vaziri
Journal:  West J Med       Date:  1984-04

Review 9.  Mineralocorticoid receptor antagonists and hypertension: is there a rationale?

Authors:  Olga Gumieniak; Gordon H Williams
Journal:  Curr Hypertens Rep       Date:  2004-08       Impact factor: 5.369

10.  Therapeutic value of calcium antagonists in autonomous hyperaldosteronism.

Authors:  M Stimpel; K Ivens; H P Volkmann; G Wambach; W Kaufmann
Journal:  Klin Wochenschr       Date:  1989-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.